Sponsors

Sponsors─the lifeblood of research

 

The majority of the independent research in Denmark are financed (and implemented)
through fund-raising from public and private funds and corporations─nationally and internationally

Thus, our many years of research are achieved through annual application rounds.
donate

 

The financing of our research

is based on public and private funds and corporations

We owe a lot of funds and companies big thanks for the daring to invest long-term and visionary─even in the very beginning of our research.

We thank the many small and smaller funds that have gone into even big budgets,
with the motto: every little drop ……!!  / many a mickle makes a muckle  / Small streams make great rivers/ many small ones make a big one

 

Over the years every donation, we have received, has been crucial in bringing us
above  the annual financial finish line – where we at times
have been forced to slow down in both scope and ambition to simply continue.

We owe special thanks to the many, who patiently have assigned us a recurring funding over several years.
It is much easier to maintain confidence in the annual application rounds with the certainty of an initial capital.

Finally, we owe several big, more socially focused funds, big thank to surpass their usual practice,
and save our research at the times our economic prospects have been particularly critical.

 

The self-financing by Hvidovre Hospital

has through years passed in:

  • salary for the PI and initiator of the research Consultant, Professor, DMSc.Hans Jørgen Nielsen, Hvidovre Hospital
  • establishing, operating and maintaining the facilities for project administration at Hvidovre Hospital
  • management control and auditing of accounts through the accounting department, Hvidovre Hospital

Additionally

the participating hospitals houses the daily work functions in the project

and operation and maintenance of equipment─PCs, printers, freezers, centrifuges, etc.

are charged  to the respective  hospital departments.operating expenses.

 

Sponsorships are included

Projects of a magnitude like ours—with views to a soon coming implementation—have
many stakeholders─both academic and private biotech companies.

Besides a wide range of Danish and Swiss private funds, the project is sponsored contractually by
European and American biotech companies as well as The State Council for Strategic Research in Denmark.

Read more:    Current Sponsors

Aktuelle sponsorer2...DEL 2_august 2016
Current sponsors ….. CLICK

Commercial interests

are specifically related to the respective stakeholders’ need for valid material for the testing and analyses of
own biomarker combinations at their own analysis platforms.

Through our many years of research, we have always prioritized a thorough documentation of our project inclusions and workflows.
Also, with our many major projects we have built up a large, meticulously recorded material.
Cf. our continuous monitoring with preanalytical projects:  Our research/Additional research

 

Actual results

Today, our long list of projects reaps tangible, comprehensible results.
Before long, our research may contribute to useful clinical processes
for the benefit of many potential cancer patients.

 

Read more:

Current research      Collaborations     Our research     About us

More on budgetary and financing

 

 

 

 

 

 

 

Print Friendly, PDF & Email

Contact:

ColoRectal Cancer Research

Gastroenheden, Hvidovre Hospital

Kettegård Allé 30

2650 Hvidovre

Email: info@colorectalcancer.dk

 

1.  Recent results:

Biological markers in blood may identify subjects at risk of developing subsequent cancer diseases
Our basic research-hypothesis is confirmed as we have now shown that:
elevated levels of one or more of four biological blood-based biomarkers relate to an increased risk of developing a cancer disease within few years.

2.  Applications of research results:

Triage in screening for colorectal cancer
Future screening based on a combination of a the current FIT-screening result added the person’s age plus the result of a blood-based biomarker test
potentially reduces  the total number of colonoscopies─ executed as a result of a screening based on a FIT-test─by 25%.
and spare  the individual an unnecessary, unpleasant examination.
Read: The publication on the basic research results / published 08.03.2017

3.  Press Coverage 2018-04-13